Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 3 (2006), Issue 12 (December)

1. Novel patterns of genome rearrangement and their association with survival in breast cancer.
   Genome Res, 16(12): 1465-79. [Abstract] [Full-text]
2. Combined breast ductal lavage and ductal endoscopy for the evaluation of the high-risk breast: a feasibility study.
   J Surg Oncol, 94(7): 555-64. [Abstract] [Full-text]
3. Autocrine and juxtacrine effects of amphiregulin on the proliferative, invasive, and migratory properties of normal and neoplastic human mammary epithelial cells.
   J Biol Chem, 281(49): 37728-37. [Abstract] [Full-text]
4. Differential activation of wild-type estrogen receptor alpha and C-terminal deletion mutants by estrogens, antiestrogens and xenoestrogens in breast cancer cells.
   J Steroid Biochem Mol Biol, 103(1): 1-9. [Abstract] [Full-text]
5. Management of postmenopausal symptoms in breast cancer survivors.
   Semin Oncol, 33(6): 696-707. [Abstract] [Full-text]
6. Selecting endocrine therapy for breast cancer: what role does HER-2/neu status play?
   Semin Oncol, 33(6): 681-7. [Abstract] [Full-text]
7. Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.
   Semin Oncol, 33(6): 672-80. [Abstract] [Full-text]
8. Preservation of fertility and the impact of subsequent pregnancy in patients with premenopausal breast cancer.
   Semin Oncol, 33(6): 664-71. [Abstract] [Full-text]
9. Adjuvant hormonal therapy for premenopausal women with breast cancer.
   Semin Oncol, 33(6): 657-63. [Abstract] [Full-text]
10. Neoadjuvant endocrine therapy for locally advanced breast cancer.
    Semin Oncol, 33(6): 650-6. [Abstract] [Full-text]
11. Tamoxifen in ductal carcinoma in situ.
    Semin Oncol, 33(6): 647-9. [Abstract] [Full-text]
12. Chemoprevention of breast cancer for women at high risk.
    Semin Oncol, 33(6): 642-6. [Abstract] [Full-text]
13. Steroid receptors and their role in the biology and control of breast cancer growth.
    Semin Oncol, 33(6): 631-41. [Abstract] [Full-text]
14. Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity.
    Am J Clin Pathol, 127(1): 103-13. [Abstract] [Full-text]
15. Can core biopsy reliably diagnose mucinous lesions of the breast?
    Am J Clin Pathol, 127(1): 124-7. [Abstract] [Full-text]
16. Genomic analysis of the 8p11-12 amplicon in familial breast cancer.
    Int J Cancer, 120(3): 714-7. [Abstract] [Full-text]
17. Sexuality and intimacy issues facing women with breast cancer.
    Oncol Nurs Forum, 33(6): 1163-7. [Abstract] [Full-text]
18. Breast cancer risk and immune responses in healthy women.
    Oncol Nurs Forum, 33(6): 1151-9. [Abstract] [Full-text]
19. The diagnosis of breast cancer: transition from health to illness.
    Oncol Nurs Forum, 33(6): 1121-7. [Abstract] [Full-text]
20. Breast cancer among Asian Americans: is acculturation related to health-related quality of life?
    Oncol Nurs Forum, 33(6): E90-9. [Abstract] [Full-text]
21. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
    Oncogene, 25(58): 7565-76. [Abstract] [Full-text]
22. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial.
    Lancet, 368(9552): 2053-60. [Abstract] [Full-text]
23. Prediction of sentinel lymph node-only disease in women with invasive breast cancer.
    Am J Surg, 192(6): 882-7. [Abstract] [Full-text]
24. Rate of malignancies in breast abscesses and argument for ultrasound drainage.
    Am J Surg, 192(6): 869-72. [Abstract] [Full-text]
25. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.
    Cancer Cell, 10(6): 529-41. [Abstract] [Full-text]
26. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
    Cancer Cell, 10(6): 515-27. [Abstract] [Full-text]
27. Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer.
    Cancer Cell, 10(6): 487-99. [Abstract] [Full-text]
28. Integrated breast cancer genomics.
    Cancer Cell, 10(6): 453-4. [Abstract] [Full-text]
29. Progressive resistance training and stretching following surgery for breast cancer: study protocol for a randomised controlled trial.
    BMC Cancer, 6: 273. [Abstract] [Full-text]
30. A prospective study of infertility due to ovulatory disorders, ovulation induction, and incidence of breast cancer.
    Arch Intern Med, 166(22): 2484-9. [Abstract] [Full-text]
31. Recreational physical activity and risk of postmenopausal breast cancer based on hormone receptor status.
    Arch Intern Med, 166(22): 2478-83. [Abstract] [Full-text]
32. Beta glucan induces proliferation and activation of monocytes in peripheral blood of patients with advanced breast cancer.
    Int Immunopharmacol, 7(1): 113-6. [Abstract] [Full-text]
33. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier.
    Anticancer Drugs, 18(1): 23-8. [Abstract] [Full-text]
34. Imaging breast cancer.
    Radiol Clin North Am, 45(1): 45-67. [Abstract] [Full-text]
35. Pro-inflammatory cytokines in elective flap surgery.
    J Surg Res, 137(1): 117-21. [Abstract] [Full-text]
36. Troponin-T and myoglobin plus echocardiographic evaluation for monitoring early cardiotoxicity of weekly epirubicin-paclitaxel in metastatic breast cancer patients.
    Anticancer Drugs, 18(2): 227-32. [Abstract] [Full-text]
37. Knowledge of breast cancer and its early detection measures among rural women in Akinyele Local Government Area, Ibadan, Nigeria.
    BMC Cancer, 6: 271. [Abstract] [Full-text]
38. Dual role of SnoN in mammalian tumorigenesis.
    Mol Cell Biol, 27(1): 324-39. [Abstract] [Full-text]
39. Genistein and quercetin increase connexin43 and suppress growth of breast cancer cells.
    Carcinogenesis, 28(1): 93-100. [Abstract] [Full-text]
40. Impact of constitutive IGF1/IGF2 stimulation on the transcriptional program of human breast cancer cells.
    Carcinogenesis, 28(1): 49-59. [Abstract] [Full-text]
41. Significance of flat epithelial atypia on mammotome core needle biopsy: Should it be excised?
    Hum Pathol, 38(1): 35-41. [Abstract] [Full-text]
42. Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance.
    Hum Pathol, 38(1): 26-34. [Abstract] [Full-text]
43. Coordinate loss of fibroblast growth factor 2 and laminin 5 expression during neoplastic progression of mammary duct epithelium.
    Hum Pathol, 38(1): 154-60. [Abstract] [Full-text]
44. Occurrence of thymosin beta4 in human breast cancer cells and in other cell types of the tumor microenvironment.
    Hum Pathol, 38(1): 114-9. [Abstract] [Full-text]
45. Direct detection of herceptin/trastuzumab binding on breast tissue sections.
    J Histochem Cytochem, 55(1): 25-33. [Abstract] [Full-text]
46. Artefact as the pathologist's friend: peritumoral retraction in in situ and infiltrating duct carcinoma of the breast.
    Int J Surg Pathol, 15(1): 53-9. [Abstract] [Full-text]
47. Breast tumor resembling the tall cell variant of papillary thyroid carcinoma: report of 4 cases with evidence of malignant potential.
    Int J Surg Pathol, 15(1): 14-9. [Abstract] [Full-text]
48. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation.
    J Natl Cancer Inst, 98(24): 1777-85. [Abstract] [Full-text]
49. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study.
    J Natl Cancer Inst, 98(24): 1767-76. [Abstract] [Full-text]
50. Trends in time to completion of mammographic screening and follow-up services.
    AJR Am J Roentgenol, 188(1): 242-5. [Abstract] [Full-text]
51. Performance parameters for screening and diagnostic mammography in a community practice: are there differences between specialists and general radiologists?
    AJR Am J Roentgenol, 188(1): 236-41. [Abstract] [Full-text]
52. Attitudes and practices of breast cancer consultations regarding sexual issues: a nationwide survey of Japanese surgeons.
    J Clin Oncol, 24(36): 5763-8. [Abstract] [Full-text]
53. Anti-aromatase activity of phytochemicals in white button mushrooms (Agaricus bisporus).
    Cancer Res, 66(24): 12026-34. [Abstract] [Full-text]
54. A systematic assessment of common genetic variation in CYP11A and risk of breast cancer.
    Cancer Res, 66(24): 12019-25. [Abstract] [Full-text]
55. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant.
    Cancer Res, 66(24): 11954-66. [Abstract] [Full-text]
56. Proteomic profiling of primary breast cancer predicts axillary lymph node metastasis.
    Cancer Res, 66(24): 11825-30. [Abstract] [Full-text]
57. Endothelins induce CCR7 expression by breast tumor cells via endothelin receptor A and hypoxia-inducible factor-1.
    Cancer Res, 66(24): 11802-7. [Abstract] [Full-text]
58. Identification of cyclin D1- and estrogen-regulated genes contributing to breast carcinogenesis and progression.
    Cancer Res, 66(24): 11649-58. [Abstract] [Full-text]
59. Multiple interacting oncogenes on the 8p11-p12 amplicon in human breast cancer.
    Cancer Res, 66(24): 11632-43. [Abstract] [Full-text]
60. SLC5A8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases.
    Cancer Res, 66(24): 11560-4. [Abstract] [Full-text]
61. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer.
    J Clin Oncol, 24(36): 5769-79. [Abstract] [Full-text]
62. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival.
    J Clin Oncol, 24(36): 5637-44. [Abstract] [Full-text]
63. Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer.
    J Clin Oncol, 24(36): 5645-51. [Abstract] [Full-text]
64. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.
    J Clin Oncol, 24(36): 5652-7. [Abstract] [Full-text]
65. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
    J Clin Oncol, 24(36): 5664-71. [Abstract] [Full-text]
66. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer.
    J Clin Oncol, 24(36): 5658-63. [Abstract] [Full-text]
67. Physical activity and breast cancer: a systematic review.
    Epidemiology, 18(1): 137-57. [Abstract] [Full-text]
68. Improved breast cancer prognosis through the combination of clinical and genetic markers.
    Bioinformatics, 23(1): 30-7. [Abstract] [Full-text]
69. Decreased prevalence of asymptomatic choroidal metastasis in disseminated breast and lung cancer: argument against screening.
    Br J Ophthalmol, 91(1): 74-5. [Abstract] [Full-text]
70. The clinical significance of disseminated tumor cells in breast cancer.
    Nat Clin Pract Oncol, 4(1): 30-41. [Abstract] [Full-text]
71. Importance of comparison of current and prior mammograms in breast cancer screening.
    Radiology, 242(1): 70-7. [Abstract] [Full-text]
72. Characterization of benign and malignant solid breast masses: comparison of conventional US and tissue harmonic imaging.
    Radiology, 242(1): 63-9. [Abstract] [Full-text]
73. Underestimation of the presence of breast carcinoma in papillary lesions initially diagnosed at core-needle biopsy.
    Radiology, 242(1): 58-62. [Abstract] [Full-text]
74. The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models.
    Mol Pharmacol, 71(1): 240-9. [Abstract] [Full-text]
75. TEXAS (Taxotere EXperience with Anthracyclines Study) trial: mature results of activity/toxicity of docetaxel given with anthracyclines in a community setting, as first line therapy for MBC.
    Cancer Chemother Pharmacol, 59(3): 413-8. [Abstract] [Full-text]
76. Cisplatin's tumoricidal effect on human breast carcinoma MCF-7 cells was not attenuated by American ginseng.
    Cancer Chemother Pharmacol, 59(3): 369-74. [Abstract] [Full-text]
77. Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedules.
    Invest New Drugs, 25(2): 161-4. [Abstract] [Full-text]
78. Role of axillary ultrasound examination in the selection of breast cancer patients for sentinel node biopsy.
    Am J Surg, 193(1): 16-20. [Abstract] [Full-text]
79. Does patient satisfaction with breast reconstruction change over time? Two-year results of the Michigan Breast Reconstruction Outcomes Study.
    J Am Coll Surg, 204(1): 7-12. [Abstract] [Full-text]
80. Long-term results of breast cancer irradiation treatment with low-dose-rate external irradiation.
    Int J Radiat Oncol Biol Phys, 67(1): 117-21. [Abstract] [Full-text]
81. HER2 testing: a review of detection methodologies and their clinical performance.
    Expert Rev Mol Diagn, 7(1): 53-64. [Abstract] [Full-text]
82. Prognostic value of the apoptosis related genes BCL2 and BCL2L12 in breast cancer.
    Cancer Lett, 247(1): 48-55. [Abstract] [Full-text]
83. Ki-67, p53, ER receptors, ploidy and S phase as long-term prognostic factors in T1 node-negative breast cancer.
    Tumour Biol, 28(1): 45-51. [Abstract] [Full-text]
84. Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
    N Engl J Med, 355(26): 2733-43. [Abstract] [Full-text]
85. Incidence of venous thromboembolism and the impact on survival in breast cancer patients.
    J Clin Oncol, 25(1): 70-6. [Abstract] [Full-text]
86. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
    J Clin Oncol, 25(1): 118-45. [Abstract] [Full-text]
87. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.
    J Clin Oncol, 25(1): 64-9. [Abstract] [Full-text]
88. Increased risk of breast cancer associated with CHEK2*1100delC.
    J Clin Oncol, 25(1): 57-63. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.